Dual antiplatelet therapy after drug-eluting stent implantation: Is it time to slacken the reins?

Journal of the American College of Cardiology

Volumn 60, Issue 15, 2012, Pages 1349-1351

  Witzenbichler, Bernhard ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

antiplatelet therapy; coronary artery disease; drug eluting stents

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYPHER; EVEROLIMUS; PACLITAXEL; PURINERGIC P2 RECEPTOR ANTAGONIST; RAPAMYCIN; UMIROLIMUS; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ANTICOAGULANT THERAPY; ANTIPROLIFERATIVE ACTIVITY; BARE METAL STENT; BLEEDING; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DISEASE ASSOCIATION; DRUG ELUTING STENT; DRUG SAFETY; HUMAN; IN-STENT RESTENOSIS; MATERIAL COATING; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NOTE; PATIENT COMPLIANCE; POSTOPERATIVE CARE; PRIORITY JOURNAL; RISK FACTOR; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT WITHDRAWAL; UNSTABLE ANGINA PECTORIS;

EID: 84867084233     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.08.003     Document Type: Editorial

References (22)

1. F. Airoldi, A. Colombo, N. Morici Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment Circulation 116 2007 745 754
2. I. Iakovou, T. Schmidt, E. Bonizzoni Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 2005 2126 2130
3. J.A. Spertus, R. Kettelkamp, C. Vance Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry Circulation 113 2006 2803 2809
4. B. Lagerqvist, S.K. James, U. Stenestrand, J. Lindback, T. Nilsson, L. Wallentin Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden N Engl J Med 356 2007 1009 1019
5. M. Pfisterer, H.P. Brunner-La Rocca, P.T. Buser Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents J Am Coll Cardiol 48 2006 2584 2591
6. G.N. Levine, E.R. Bates, J.C. Blankenship et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 e122
7. W. Wijns, P. Kolh, N. Danchin Guidelines on myocardial revascularization Eur Heart J 31 2010 2501 2555
8. L. Raber, M. Magro, G.G. Stefanini Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study Circulation 125 2012 1110 1121
9. G.G. Stefanini, R.A. Byrne, P.W. Serruys Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials Eur Heart J 33 2012 1214 1222
10. T. Palmerini, G. Biondi-Zoccai, D. Della Riva Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis Lancet 379 2012 1393 1402
11. K. Kolandaivelu, R. Swaminathan, W.J. Gibson Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings Circulation 123 2011 1400 1409
12. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
13. T. Tada, M. Natsuaki, T. Morimoto CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2 Circ Cardiovasc Interv 5 2012 381 391
14. G. Ndrepepa, P.B. Berger, J. Mehilli Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point J Am Coll Cardiol 51 2008 690 697
15. B.-K. Kim, M.-K. Hong, D.-H. Shin A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation J Am Coll Cardiol 60 2012 1340 1348
16. D.E. Kandzari, L. Mauri, J.J. Popma Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) J Am Coll Cardiol Intv 4 2011 543 550
17. K. Rasmussen, M. Maeng, A. Kaltoft Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial Lancet 375 2010 1090 1099
18. M.B. Leon, E. Nikolsky, D.E. Cutlip Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial J Am Coll Cardiol Intv 3 2010 1043 1050
19. I. Ferreira-González, J.R. Marsal, A. Ribera Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year J Am Coll Cardiol 60 2012 1333 1339
20. I. Ferreira-Gonzalez, J.R. Marsal, A. Ribera Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation Circulation 122 2010 1017 1025
21. S. Schulz, T. Schuster, J. Mehilli Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period Eur Heart J 30 2009 2714 2721
22. M.A. Gaglia Jr., R. Waksman Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes Eur Heart J 32 2011 2358 2364